Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Teva Pharmaceutical Industries FCF Margin %?
Teva Pharmaceutical IndustriesLTS:0LER +6.27%45 FCF Margin % is 7.41% as of Jun. 2026, which is 29% above its 10-year median of 5.75. GuruFocus rates LTS:0LER with a GF Score™ of 45/100 and a GF Value™ of $20.76 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 963 Drug Manufacturers companies, Teva Pharmaceutical Industries ranks better than 64.69% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0LER vs ZTS, UTHR, VTRS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teva Pharmaceutical Industries FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Teva Pharmaceutical Industries's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Teva Pharmaceutical Industries (LTS:0LER) has a FCF Margin % of 7.41% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Teva Pharmaceutical Industries and its competitors. This is 29% above median its historical median of 5.75. Over the past decade, Teva Pharmaceutical Industries' FCF Margin % has ranged from 1.32 to 13.65. According to the industry distribution chart, Teva Pharmaceutical Industries ranks #340 out of 963 companies in the Drug Manufacturers industry, placing it in the top 35.3%.
Is Teva Pharmaceutical Industries' FCF Margin % too high?
Teva Pharmaceutical Industries' current FCF Margin % of 7.41% is 29% above median its 10-year median of 5.75. Over the past 10 years, this metric has ranged from a low of 1.32 to a high of 13.65. The Drug Manufacturers industry median FCF Margin % is 2.58. Teva Pharmaceutical Industries' value of 7.41% is 187.2% above this industry median. Based on the distribution chart, Teva Pharmaceutical Industries ranks #340 out of 963 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Teva Pharmaceutical Industries has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Teva Pharmaceutical Industries ranks #340 out of 963 companies for FCF Margin %. This puts Teva Pharmaceutical Industries in the upper half of its industry. The industry median FCF Margin % is 2.58. Teva Pharmaceutical Industries' value of 7.41% is 187.2% above this benchmark. Historically, Teva Pharmaceutical Industries' own FCF Margin % has ranged from 1.32 to 13.65 over the past decade. While the company's 10-year median is 5.75 vs. the industry median of 2.58, Teva Pharmaceutical Industries has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.58, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Teva Pharmaceutical Industries's current FCF Margin % of 7.41% is 187.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Teva Pharmaceutical Industries and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Teva Pharmaceutical Industries's current FCF Margin % is 7.41%, which is 29% above median its own 10-year median of 5.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (LTS:0LER) is currently considered Significantly Overvalued. The stock's GF Value™ is $20.76, compared to a current price of $35.60 — trading 71.5% above its estimated fair value. The current FCF Margin % is 7.41%, which is 29% above median its 10-year median of 5.75 and 187.2% above the Drug Manufacturers industry median of 2.58. Teva Pharmaceutical Industries' overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Teva Pharmaceutical Industries (LTS:0LER), the current FCF Margin % is 7.41% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Teva Pharmaceutical Industries (LTS:0LER) Overvalued in 2026?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued.
The current stock price of $35.60 is trading 71.5% above its estimated GF Value™ of $20.76.
GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.
Key valuation signals for LTS:0LER:
FCF Margin %: 7.41% (29% above median its 10-year median of 5.75)
GF Value™: $20.76 vs. price of $35.60 (71.5% above fair value)
Industry Position: 187.2% above the Drug Manufacturers median (#340 of 963)
No single metric tells the full story. See the LTS:0LER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
45GF Score
Get the complete analysis for LTS:0LER
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LER has been successfully added to your 
